TEVA (NYSE) insider filing: 62,102 ordinary shares planned for sale via Citigroup

Rhea-AI Filing Summary

Teva Pharmaceutical Industries reported a Form 144 notification for the proposed sale of 62,102 ordinary shares, listed for sale through Citigroup Global Markets Inc. on the NYSE. The shares are identified as rollover/compensation ordinary shares with trade dates listed in March 2026.

Insights

Securities Compliance Analyst

Routine Form 144 filing showing planned dispositions totaling 62,102 ordinary shares.

The filing lists 62,102 ordinary shares to be sold via Citigroup Global Markets Inc. and classifies the shares as shares from rollover and compensation ordinary shares. The dates associated in the excerpt are in March 2026.

These entries are a notice of intended sale under resale rules; cash‑flow treatment and whether sales have executed are not stated in the excerpt. Subsequent SEC reports would show execution details and quantities actually sold.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	62102	1871815.26	1149812898	03/17/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/04/2025	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			18601	03/17/2026	COMPENSATION
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			24900	03/17/2026	COMPENSATION
ORDINARY SHARES	03/04/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			18601	03/17/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TEVA Form 144 report say about shares to be sold?

The filing lists 62,102 ordinary shares slated for sale and identifies them as rollover and compensation shares. The sales are arranged through Citigroup Global Markets Inc. with dates in March 2026.

Does the Form 144 confirm the shares have already been sold by TEVA insiders?

No. The Form 144 excerpt is a notification of intended disposition; it does not confirm execution. The excerpt lists planned sale entries and dates in March 2026, but execution details are not provided here.

Who is the broker handling the proposed TEVA share sales?

The broker named in the excerpt is Citigroup Global Markets Inc. at 390 Greenwich Street, New York. The filing lists this broker in association with the proposed sale of the ordinary shares.

What types of shares are being offered in the TEVA Form 144?

The excerpt classifies the securities as ordinary shares described as shares from rollover and compensation ordinary shares. Those labels appear alongside the per‑entry share quantities in March 2026.

Are dollar amounts or proceeds disclosed in the TEVA excerpt?

The provided excerpt does not disclose sale proceeds or dollar amounts. It lists share counts and broker details but does not state aggregate sale proceeds or prices in the excerpt.